Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Smith

Showing results (91-100 of 319) with videos related to

Pageof 32
Sort By:
Cancer|October 16, 2012
Bone density testing among prostate cancer survivors treated with androgen-deprivation therapyAlicia K Morgans, Matthew R Smith, A James O'Malley, et al.
Clinical Genitourinary Cancer|January 26, 2020
Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate CancerMatthew R Smith, Maneesha Mehra, Sandhya Nair, et al.
Nature Reviews. Clinical Oncology|March 2, 2010
Hormonal therapies: ADT for prostate cancer: true love or heartbreak?Jason A Efstathiou, William U Shipley, Anthony L Zietman, et al.
BJU International|September 24, 2010
Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention?John J Coen, Adam S Feldman, Matthew R Smith, et al.
Journal of the National Cancer Institute|December 10, 2009
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancerNancy L Keating, A James O'Malley, Stephen J Freedland, et al.
Current Medical Research and Opinion|November 19, 2010
Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasisHind T Hatoum, Swu-Jane Lin, Amy Guo, et al.
Clinical Breast Cancer|June 14, 2011
Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasisHind T Hatoum, Swu-Jane Lin, Matthew R Smith, et al.
Plos One|January 26, 2016
Global Expanded Nutrient Supply (GENuS) Model: A New Method for Estimating the Global Dietary Supply of NutrientsMatthew R Smith, Renata Micha, Christopher D Golden, et al.
The Oncologist|October 5, 2007
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activityAllan Lipton, Richard J Cook, Pierre Major, et al.
Food and Nutrition Bulletin|April 13, 2019
Inadequate Zinc Intake in India: Past, Present, and FutureMatthew R Smith, Ruth DeFries, Ashwini Chhatre, et al.
Pageof 32

Showing results (91-100 of 319) with videos related to

Sort By:
Pageof 32
Cancer|October 16, 2012
Bone density testing among prostate cancer survivors treated with androgen-deprivation therapyAlicia K Morgans, Matthew R Smith, A James O'Malley, et al.
Clinical Genitourinary Cancer|January 26, 2020
Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate CancerMatthew R Smith, Maneesha Mehra, Sandhya Nair, et al.
Nature Reviews. Clinical Oncology|March 2, 2010
Hormonal therapies: ADT for prostate cancer: true love or heartbreak?Jason A Efstathiou, William U Shipley, Anthony L Zietman, et al.
BJU International|September 24, 2010
Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention?John J Coen, Adam S Feldman, Matthew R Smith, et al.
Journal of the National Cancer Institute|December 10, 2009
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancerNancy L Keating, A James O'Malley, Stephen J Freedland, et al.
Current Medical Research and Opinion|November 19, 2010
Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasisHind T Hatoum, Swu-Jane Lin, Amy Guo, et al.
Clinical Breast Cancer|June 14, 2011
Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasisHind T Hatoum, Swu-Jane Lin, Matthew R Smith, et al.
Plos One|January 26, 2016
Global Expanded Nutrient Supply (GENuS) Model: A New Method for Estimating the Global Dietary Supply of NutrientsMatthew R Smith, Renata Micha, Christopher D Golden, et al.
The Oncologist|October 5, 2007
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activityAllan Lipton, Richard J Cook, Pierre Major, et al.
Food and Nutrition Bulletin|April 13, 2019
Inadequate Zinc Intake in India: Past, Present, and FutureMatthew R Smith, Ruth DeFries, Ashwini Chhatre, et al.
Pageof 32